A Phase I/IIa Study of BMS-986205 Administered in Combination with Nivolumab (BMS-935558 anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

Brief description of study

If you have been diagnosed with advanced(metastatic (spread to another area of the body) and/or unresectable (cannot be removed from the body)) malignant tumors, including melanoma and non-small cell lung cancer, you may qualify to participate in a study evaluating the safety, tolerability, and toxicity levels of BMS-986205 (an inhibitor of the indoleamine 2,3- dioxygenase1) supplied as a single therapy and in combination with Nivolumab (a PD-1 agonist). The main goal of this phase I/IIa is to also investigate the anti-tumor activity of BMS-986205 administered in combination with Nivolumab in various cohorts. In addition, we would like to study blood samples to understand how BMS-986205 is in the blood over time, which is known as pharmacokinetic (PK) testing.


Clinical Study Identifier: s17-00278
ClinicalTrials.gov Identifier: NCT02658890
Principal Investigator: Daniel C Cho
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.